FDA Expands Approval of Fulvestrant for Breast Cancer - NCI
Shapiro Lab Research Areas
Fulvestrant in advanced breast cancer: evidence to date and place in therapy - Katalin Boér, 2017
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer | Breast Cancer Research | Full Text
Pure Antiestrogens - Selective Estrogen Receptor Modulators. Antonio Cano
IJMS | Free Full-Text | Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
Treatment of Metastatic Breast Cancer: Endocrine | Oncohema Key
Fulvestrant | SpringerLink
Fulvestrant | Uses, Brand Names, Mechanism Of Action
Comparative Efficacy of AZD9496 and Fulvestrant on the Growth of Pituitary Adenoma via Blocking JAK2/STAT5B Pathway
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
RESEARCH - JESELSOHN LAB - TRANSLATIONAL BREAST CANCER RESEARCH
Estrogen Receptor Modulator - an overview | ScienceDirect Topics
Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal wom
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
Fulvestrant ('Faslodex')—a new hormonal treatment for advanced breast cancer - ScienceDirect
The molecular mechanism for the pure steroidal ERα antagonist,... | Download Scientific Diagram
Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1) - Annals of Oncology
Breast Cancer Update - Lynn Sage 2001
Estrogen alpha receptor antagonists for the treatment of breast cancer: a review | BMC Chemistry | Full Text
Fulvestrant - LiverTox - NCBI Bookshelf
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
